(Nov 25): Novartis AG agreed to buy Medicines Co. for an equity value of about US$6.8 billion ($9.3 billion), snapping up a promising cholesterol drug and adding to a string of acquisitions for Chief Executive Officer Vas Narasimhan.

Medicines Co. shareholders will get US$85 a share, Basel, Switzerland-based Novartis said in a statement Sunday. That’s a 45% premium to the closing price on Nov. 18, before Bloomberg reported the two companies were in talks. The transaction value reaches $9.7 billion on a fully diluted basis that includes outstanding stock options and convertible debt, Novartis said.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply


Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook